乳腺癌基因组改变:根据ESMO分子靶点临床可操作性量表(ESCAT)的证据等级
该文依据ESMO分子靶点临床可操作性量表(ESCAT),对乳腺癌中约40种复发驱动基因改变进行证据等级排序,以帮助临床医生优先选择治疗。ERBB2扩增、胚系BRCA1/2突变和PIK3CA突变被列为IA级;NTRK融合和微卫星不稳定(MSI)为IC级;ESR1突变和PTEN缺失为IIA级;ERBB2突变和AKT1突变为IIB级;体细胞BRCA1/2突变、MDM2扩增和ERBB3突变为III级;17个基因基于临床前证据列为IV级;FGFR1和CCND1因既往研究显示缺乏可操作性列为X级。
要点
- ERBB2扩增、胚系BRCA1/2突变、PIK3CA突变被列为ESCAT IA级证据。
- NTRK融合和MSI列为IC级;ESR1突变和PTEN缺失为IIA级。
- FGFR1和CCND1因既往研究显示缺乏可操作性被列为X级。
核心结论
- 基于ESCAT对乳腺癌复发基因组改变进行证据等级排序,以帮助临床医生优先选择治疗。
研究设计与样本
- 本文为基于ESCAT量表的证据等级排序分析,分析数据库提示乳腺癌中约有40种复发驱动基因改变。
主要发现
- ERBB2扩增、胚系BRCA1/2突变和PIK3CA突变被列为IA级证据,基于大型随机试验显示靶向治疗在携带这些改变的患者中具有抗肿瘤活性。
- NTRK融合和微卫星不稳定(MSI)被列为IC级。
- ESR1突变和PTEN缺失被列为IIA级,ERBB2突变和AKT1突变被列为IIB级。
- 体细胞BRCA1/2突变、MDM2扩增和ERBB3突变被列为III级,17个基因基于临床前证据被列为IV级。
- FGFR1和CCND1因既往研究显示缺乏可操作性被列为X级改变。
关键数值与推荐
- ERBB2扩增、胚系BRCA1/2突变、PIK3CA突变为ESCAT IA级。
- NTRK融合和MSI为IC级;ESR1突变和PTEN缺失为IIA级;ERBB2突变和AKT1突变为IIB级。
- 体细胞BRCA1/2突变、MDM2扩增和ERBB3突变为III级;17个基因基于临床前证据为IV级;FGFR1和CCND1为X级。
临床怎么用
- 原文未据此给出具体临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Better knowledge of the tumor genomic landscapes has helped to develop more effective targeted drugs. However, there is no tool to interpret targetability of genomic alterations assessed by next-generation sequencing in the context of clinical practice. Our aim is to rank the level of evidence of individual recurrent genomic alterations observed in breast cancer based on the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) in order to help the clinicians to prioritize treatment. Analyses of databases suggested that there are around 40 recurrent driver alterations in breast cancer. ERBB2 amplification, germline BRCA1/2 mutations, PIK3CA mutations were classified tier of evidence IA based on large randomized trials showing antitumor activity of targeted therapies in patients presenting the alterations. NTRK fusions and microsatellite instability (MSI) were ranked IC. ESR1 mutations and PTEN loss were ranked tier IIA, and ERBB2 mutations and AKT1 mutations tier IIB. Somatic BRCA 1/2 mutations, MDM2 amplifications and ERBB 3 mutations were ranked tier III. Seventeen genes were ranked tier IV based on preclinical evidence. Finally, FGFR1 and CCND1 were ranked tier X alterations because previous studies have shown lack of actionability.
引用
- Condorelli R, Mosele F, Verret B, et al. Genomic alterations in breast cancer: level of evidence for actionability according to ESMO Scale for Clinical Actionability of molecular Targets (ESCAT). Ann Oncol. 2019. PMID: 30715161. doi:10.1093/annonc/mdz036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。